COSMOS HEALTH INC
COSMNASDAQTrading Snapshot
- Day Range
- $0.24 – $0.26
- 52-Week Range
- $0.16 – $1.04
- Volume (shares)
- 2,627,659
- Avg Volume (shares)
- —
- Shares Outstanding
- 100.6M
- Next Earnings
- 2026-11-17
Fundamentals Snapshot
- Annual Revenue
- $65M
- Last Q Revenue
- $19M
- P/E Ratio
- -0.4
- P/S Ratio
- 0.3x
- EPS (TTM)
- $-0.41
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +58.2%
COSMOS HEALTH INC
COSM
StockOtter · stockotter.spaceAbout COSMOS HEALTH INC
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway
Now live in Oceania: e-commerce subscription business operating across Australia, New Zealand and the broader Oceania region, with sales already underway Attractive markets: together, Australia and New Zealand represent
Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion
Key Highlights Record revenue: preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, with every quarter of 2026 setting a record 2026 outlook reaffirmed: full-year revenue expected to surpass $90 mi
Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days
● Q4 2026 U.S. revenue: approximately $15 million expected, based on the Company's current growth trajectory ● Q4 2026 gross profit: approximately $10.5 million expected, at an approximately 70% gross margin ● Subscripti
Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
● 6,287 active U.S. subscriptions as of October 14, 2026, the vast majority added since mid-September as the Company accelerates investment in its U.S. platform ● 60.5% of U.S. online checkout orders included a subscript
Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
Record day: U.S. direct-to-consumer sales exceeded $92,000 on October 11, 2026, the highest single day to date $902,000 in 30 days: approximately $30,000 in average daily sales over the trailing 30-day period Acceleratin
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
Record nine-month revenue of approximately $54.3 million - up 19%, or $8.7 million, from $45.6 million in the same period of 2025 Nine-month 2026 revenue nearly matches the whole of 2024 - when full-year revenue was $54.